Sponsored Post

How Can RWD Transform the Patient Journey?

A one-size fits most approach to clinical trial recruitment is no longer effective. A webinar discussion emphasized the need for patient-level data to shape each phase of a drug’s lifecycle, from clinical development to market access.

presented by

The digitization of data, changes to how patient data is shared, and a wealth of real-world data (RWD) mean hospitals and drug developers can form richer insights on patient populations, improve clinical trial recruitment and develop more effective treatments for chronic conditions. But challenges to accessing and interpreting this data remain. These were some of the talking points of a webinar sponsored by PurpleLab, Eliminating Blind Spots in the Patient Journey.

Webinar panelists included Steve Emrick, PurpleLab senior vice president of clinical informatics solutions and health nexus; Russ Cobb, PurpleLab chief marketing officer; and Dr. Ben Freiberg, Principal Informatics Systems Lead with Genentech’s gCS Computational Catalysts. Genentech is part of Roche.

RWD can include data from an electronic medical record, medical claims data, data from disease registries or from connected devices.

“When we look at large data sets, we need to think about what questions do we need the data to answer? If you’ve got clarity around that, then that can help filter out the noise,” Emrick said. “So with any patient journey, such as non-small cell lung cancer, when did the patient first start to have symptoms? What was the diagnosis? What type of medication did they get? Is it a targeted therapy versus a non-targeted therapy? Were there biomarker tests that were run? If not, why did they have access to that kind of treatment?”

Freiberg observed that the more people can understand patient data beyond electronic medical records, the easier it will be to detect disease patterns and develop novel insights based on that information.

The webinar also highlighted:

  • Value of getting more Social Determinants of Health (SDoH) data
  • The influence of SDoH data in oncology
  • Personalized marketing to patients
  • Using RWD to transform clinical trial recruitment, clinical endpoints, and inform market access strategies

To access a recording of the webinar Eliminating Blind Spots in the Patient Journey, fill in the form below.

Picture: yuoak, Getty Images